KYMR — Kymera Therapeutics Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareAdventurousLarge CapNeutral

Annual balance sheet for Kymera Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	442	407	375	489	848
Net Total Accounts Receivable
Net Total Receivables	0.135	2.54	18.8	0.947	—
Prepaid Expenses
Total Current Assets	451	419	405	510	871
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	21.3	22.2	101	97.9	85.5
Long Term Investments
Other Long Term Assets
Total Assets	606	603	576	978	1,743
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	92.5	71.3	85.7	67.8	83.2
Capital Lease Obligations
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	146	113	181	142	163
Non Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	460	490	395	836	1,580
Total Liabilities & Shareholders' Equity	606	603	576	978	1,743
Total Common Shares Outstanding